Female Urology

"Every time I leave the meeting, I just feel reinvigorated, refreshed, and excited about this field that we're a part of," says Raveen Syan, MD, FPMRS.

"I don't think 1 database study creates dogma, but I do think we can share these data with our patients and talk to them about treatment options and risk, have that difficult conversation about how BMI may be associated with that risk," says Cassandra K. Kisby, MD, MS.

"The most important thing that I think came out of this study is really the BMI inflection point for complications. We saw an abrupt rise in complications around a BMI of 40," says Cassandra K. Kisby, MD, MS.

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.

Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.

The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.

Iterum plans to resubmit a New Drug Application for oral sulopenem for the treatment of patients with uUTi in Q2 of 2024.

The goals of the American Urogynecologic Society (AUGS) program are to support novel clinical, translational, and bench research pilot projects and enable early career investigators to obtain future independent funding for research.

There are several new CPT codes for 2024, including Category III codes for tibial nerve stimulation and other changes to codes in the treatment of urinary incontinence.

NRX-101 is a fixed-dose combination of the broad-spectrum antibiotic D-cycloserine and lurasidone.

“The bladder muscle can get weak as you get older, so developing urinary incontinence or ur-gency is very common as you get older,” says Vikas Desai, MD.

Amy Luckenbaugh, MD, is an assistant professor of Urology at Vanderbilt University Medical Center.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

“I think being younger and going through something so scary, I think it's been really important to her to have someone with her throughout the whole process,” says Bree Duncan, RN, BSN.

Hadley Wood, MD, shares her vision as the new editor-in-chief of Urology.

"There are a lot of questions and issues regarding [topics] like body image and sexual function, and things like that, that also, being a woman in this role, I feel like they feel comfortable asking me those questions," says Bree Duncan, RN, BSN.

"I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB," says Holly Robinson Peete.

"My goal is to always meet them there in clinic, and then just start that relationship, in a sense of, I'm there for whatever they need," says Bree Duncan, RN, BSN.

"We as a specialty have to do a better job of educating our colleagues and referring docs," says Roger R. Dmochowski, MD, MMHC, FACS

"The background for this paper stems from the increasingly identified need to do a better job of management of urinary tract infection, not only from a recognition standpoint, but also from a diagnostic and treatment standpoint," says Roger R. Dmochowski, MD, MMHC, FACS.

“This study confirms what many women who’ve struggled with persistent UTIs already know, which is that the current methods of diagnosing and treating these infections are inadequate," says Jennifer Rohn, PhD.